Skip to main content

Disc Medicine Inc

For the period ended Sep 30, 2024. Filed Nov 12, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 12, 2024

IRON$84.64+4.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations and Comprehensive Loss

Three Months EndedSeptember 30, · Nine Months EndedSeptember 30,
2024 · ​ · 2023 · 2024 · ​ · 2023
Operating expenses: · ​ · ​
Research and development$24,685$14,419$71,874​$46,699
General and administrative8,1714,53923,296​14,712
Total operating expenses32,856​18,95895,170​61,411
Loss from operations(32,856)​(18,958)(95,170)​(61,411)
Other income (expense), net:​​
Interest income6,3624,84315,454​10,120
Change in fair value of contingent value right liability———​(1,500)
Other income (expense)913(5)​8
Total other income (expense), net6,371​4,85615,449​8,628
Loss before income taxes(26,485)​(14,102)(79,721)​(52,783)
Income tax expense(114)(20)(179)(67)
Net loss$(26,599)​$(14,122)$(79,900)​$(52,850)
Net loss attributable to common stockholders-basic and diluted$(26,599)​$(14,122)$(79,900)​$(52,850)
Weighted-average common shares outstanding-basic and diluted29,935,55124,316,81726,809,60521,605,202
Net loss per share attributable to common stockholders-basic and diluted$(0.89)​$(0.58)$(2.98)​$(2.45)
Comprehensive loss:
Net loss$(26,599)$(14,122)$(79,900)$(52,850)
Other comprehensive income:
Foreign currency translation adjustments(48)—(42)—
Unrealized gain on marketable securities849—783—
Total other comprehensive income801—741—
Comprehensive loss$(25,798)$(14,122)$(79,159)$(52,850)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.